| The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent RM Mancina, P Dongiovanni, S Petta, P Pingitore, M Meroni, R Rametta, ... Gastroenterology 150 (5), 1219-1230. e6, 2016 | 651 | 2016 |
| Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores C Bianco, O Jamialahmadi, S Pelusi, G Baselli, P Dongiovanni, I Zanoni, ... Journal of hepatology 74 (4), 775-782, 2021 | 253 | 2021 |
| Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: results from a multicenter randomized double-blind placebo … L Elli, C Tomba, F Branchi, L Roncoroni, V Lombardo, MT Bardella, ... Nutrients 8 (2), 84, 2016 | 225 | 2016 |
| C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation P Cirillo, P Golino, P Calabro, G Calì, M Ragni, S De Rosa, G Cimmino, ... Cardiovascular research 68 (1), 47-55, 2005 | 217 | 2005 |
| Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease O Jamialahmadi, RM Mancina, E Ciociola, F Tavaglione, PK Luukkonen, ... Gastroenterology 160 (5), 1634-1646. e7, 2021 | 101 | 2021 |
| Nursing issues in enteral nutrition during prone position in critically ill patients: A systematic review of the literature A Bruni, E Garofalo, L Grande, G Auletta, D Cubello, M Greco, ... Intensive and Critical Care Nursing 60, 102899, 2020 | 46 | 2020 |
| Safety profiles of biologic agents for inflammatory bowel diseases: A prospective pharmacovigilance study in Southern Italy R Roberti, LF Iannone, C Palleria, C De Sarro, R Spagnuolo, MA Barbieri, ... Current medical research and opinion 36 (9), 1457-1463, 2020 | 43 | 2020 |
| Gastrointestinal symptoms of and psychosocial changes in inflammatory bowel disease: a nursing-led cross-sectional study of patients in clinical remission RM Mancina, R Pagnotta, C Pagliuso, V Albi, D Bruno, P Garieri, P Doldo, ... Medicina 56 (1), 45, 2020 | 41 | 2020 |
| Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) G Fiorino, F Caprioli, M Daperno, F Mocciaro, M Principi, A Viscido, ... Digestive and Liver Disease 51 (5), 632-639, 2019 | 40 | 2019 |
| PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes RM Mancina, R Spagnuolo, M Milano, S Brogneri, A Morrone, C Cosco, ... Inflammatory Bowel Diseases 22 (1), 134-140, 2016 | 39 | 2016 |
| DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection MA Burza, BM Motta, RM Mancina, P Pingitore, C Pirazzi, SM Lepore, ... Hepatology 63 (2), 418-427, 2016 | 37 | 2016 |
| PCSK9 rs11591147 R46L loss‐of‐function variant protects against liver damage in individuals with NAFLD S Grimaudo, S Bartesaghi, R Rametta, F Marra, R Margherita Mancina, ... Liver International 41 (2), 321-332, 2021 | 32 | 2021 |
| Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study D Pugliese, G Privitera, F Crispino, N Mezzina, F Castiglione, G Fiorino, ... Alimentary pharmacology & therapeutics 56 (1), 95-109, 2022 | 30 | 2022 |
| Deregulation of SGK1 in ulcerative colitis: a paradoxical relationship between immune cells and colonic epithelial cells R Spagnuolo, V Dattilo, L D’Antona, C Cosco, R Tallerico, V Ventura, ... Inflammatory bowel diseases 24 (9), 1967-1977, 2018 | 30 | 2018 |
| Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome R Spagnuolo, C Cosco, RM Mancina, G Ruggiero, P Garieri, V Cosco, ... European Review for Medical and Pharmacological Sciences 21 (2 Suppl), 102-107, 2017 | 28 | 2017 |
| Metabolic-dysfunction-associated fatty liver disease and gut microbiota: From fatty liver to dysmetabolic syndrome L Abenavoli, GGM Scarlata, E Scarpellini, L Boccuto, R Spagnuolo, ... Medicina 59 (3), 594, 2023 | 21 | 2023 |
| Anti‐interleukin 12/23 in the treatment of erythema nodosum and Crohn disease: A case report R Spagnuolo, S Dastoli, M Silvestri, C Cosco, P Garieri, L Bennardo, ... Dermatologic Therapy 32 (2), e12811, 2019 | 20 | 2019 |
| Gut microbiota in non-alcoholic fatty liver disease patients with inflammatory bowel diseases: a complex interplay L Abenavoli, L Giubilei, AC Procopio, R Spagnuolo, F Luzza, L Boccuto, ... Nutrients 14 (24), 5323, 2022 | 19 | 2022 |
| Long‐term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study S Festa, ML Scribano, D Pugliese, C Bezzio, M Principi, DG Ribaldone, ... UEG Journal 9 (4), 507-516, 2021 | 19 | 2021 |
| Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank F Tavaglione, A De Vincentis, O Jamialahmadi, R Pujia, R Spagnuolo, ... JHEP Reports 3 (3), 100262, 2021 | 16 | 2021 |
